Changes in salivary biomarkers of burning mouth syndrome patients after clonazepam treatment

There is a lack of objective indicators to evaluate the treatment effect of burning mouth syndrome, a neuropathic pain of unknown causes. Therefore, this study aimed to evaluate potential salivary biomarkers by analyzing saliva before and after clonazepam treatment in patients with burning mouth syndrome. Saliva was collected from 23 patients with burning mouth syndrome before and 4 weeks after the topical administration of clonazepam. Patients were classified as responders (pain relief of 50% or more, n = 10) or non-responders (n = 13) based on pain relief after treatment. Clinical examination data of responders and non-responders were compared using Mann-Whitney U test and Fisher’s exact test. Changes in the level of salivary biomarkers (salivary α-amylase, cortisol, calmodulin, α-enolase and interleukin-18) were evaluated before and after treatment using Wilcoxon signed-rank sum test, and their association with treatment response was examined using Fisher’s exact test. The salivary biomarker levels showed no significant differences between the responders and non-responders. However, the change in salivary α-amylase activity after treatment revealed a significant difference between the two groups (p = 0.039). Although not all patients showed the same pattern, there was a difference in the alteration of salivary α-amylase activity before and after treatment between responders and non-responders. Further study is required to clarify whether there is a causal relationship between salivary α-amylase activity and treatment response. However, considering that salivary α-amylase activity is related to orofacial pain and psychological stress, this suggests the potential use of salivary α-amylase as a biomarker for burning mouth syndrome.

Burning mouth syndrome; Salivary biomarker; Salivary α-amylase; Clonazepam

[1] Weiss AL, Ehrhardt KP, Tolba R. Atypical facial pain: a comprehensive, evidence-based review. Current Pain and Headache Reports. 2017; 21: 8.

[2] Pereira SR, Tello Velasquez J, Duggan S, Ivanisevic B, McKenna JP, McCreary C, et al. Recent advances in the understanding of the aetiology and therapeutic strategies in burning mouth syndrome: Focus on the actions of cannabinoids. European Journal of Neuroscience. 2022; 55: 1032–1050.

[3] Adamo D, Spagnuolo G. Burning mouth syndrome: an overview and future perspectives. International Journal of Environmental Research and Public Health. 2022; 20: 682.

[4] de Lima-Souza RA, Pérez-de-Oliveira ME, Normando AGC, Louredo BVR, Mariano FV, Farag AM, et al. Clinical and epidemiological profile of burning mouth syndrome patients following the International Headache Society classification: a systematic review and meta-analysis. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2024; 137: 119–135.

[5] Carreño-Hernández I, Cassol-Spanemberg J, de Rivera-Campillo E, Estrugo-Devesa A, López-López J. Is burning mouth syndrome a neuropathic pain disorder? A systematic review. Journal of Oral & Facial Pain and Headache. 2021; 35: 218–229.

[6] Khawaja SN, Alaswaiti OF, Scrivani SJ. Burning mouth syndrome. Dental Clinics of North America. 2023; 67: 49–60.

[7] Adamo D, Calabria E, Canfora F, Coppola N, Pecoraro G, D’Aniello L, et al. Burning mouth syndrome: analysis of diagnostic delay in 500 patients. To be published in Oral Diseases. 2023. [Preprint].

[8] Nosratzehi T. Burning mouth syndrome: a review of therapeutic approach. Journal of Complementary and Integrative Medicine. 2022; 19: 83–90.

[9] Thakkar J, Dym H. Management of burning mouth syndrome. Dental Clinics of North America. 2024; 68: 113–119.

[10] Tan HL, Smith JG, Hoffmann J, Renton T. A systematic review of treatment for patients with burning mouth syndrome. Cephalalgia. 2022; 42: 128–161.

[11] Alvarenga-Brant R, Costa FO, Mattos-Pereira G, Esteves-Lima RP, Belém FV, Lai H, et al. Treatments for burning mouth syndrome: a network meta-analysis. Journal of Dental Research. 2023; 102: 135–145.

[12] Lorenzo-Pouso AI, Pérez-Sayáns M, Bravo SB, López-Jornet P, García-Vence M, Alonso-Sampedro M, et al. Protein-based salivary profiles as novel biomarkers for oral diseases. Disease Markers. 2018; 2018: 6141845.

[13] Roi A, Rusu LC, Roi CI, Luca RE, Boia S, Munteanu RI. A new approach for the diagnosis of systemic and oral diseases based on salivary biomolecules. Disease Markers. 2019; 2019: 8761860.

[14] Ye L, Dai Q, Hou F, Wu C, Qiu X, Yuan P, et al. Salivary metabolomics of burning mouth syndrome: a cross-sectional study. Archives of Oral Biology. 2022; 144: 105552.

[15] Ji EH, Diep C, Liu T, Li H, Merrill R, Messadi D, et al. Potential protein biomarkers for burning mouth syndrome discovered by quantitative proteomics. Molecular Pain. 2017; 13: 1744806916686796.

[16] Fernández-Agra M, González-Serrano J, de Pedro M, Virto L, Caponio VCA, Ibáñez-Prieto E, et al. Salivary biomarkers in burning mouth syndrome: a systematic review and meta-analysis. Oral Diseases. 2023; 29: 2600–2613.

[17] Kim H, Kim Y, Chang J, Ko J, Kho H. Salivary cortisol, 17β-estradiol, progesterone, dehydroepiandrosterone, and α-amylase in patients with burning mouth syndrome. Oral Diseases. 2012; 18: 613–620.

[18] Krief G, Haviv Y, Deutsch O, Keshet N, Almoznino G, Zacks B, et al. Proteomic profiling of whole-saliva reveals correlation between Burning Mouth Syndrome and the neurotrophin signaling pathway. Scientific Reports. 2019; 9: 4794.

[19] Nosratzehi T, Salimi S, Parvaee A. Comparison of salivary cortisol and α-amylase levels and psychological profiles in patients with burning mouth syndrome. Special Care in Dentistry. 2017; 37: 120–125.

[20] Thakkar JP, Lane CJ. Hyposalivation and xerostomia and burning mouth syndrome. Oral and Maxillofacial Surgery Clinics of North America. 2022; 34: 135–146.

[21] Faul F, Erdfelder E, Lang A, Buchner A. G*Power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods. 2007; 39: 175–191.

[22] Arhakis A, Karagiannis V, Kalfas S. Salivary alpha-amylase activity and salivary flow rate in young adults. The Open Dentistry Journal. 2013; 7: 7–15.

[23] Amenábar JM, Pawlowski J, Hilgert JB, Hugo FN, Bandeira D, Lhüller F, et al. Anxiety and salivary cortisol levels in patients with burning mouth syndrome: case-control study. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology. 2008; 105: 460–465.

[24] Nater UM, Rohleder N. Salivary alpha-amylase as a non-invasive biomarker for the sympathetic nervous system: current state of research. Psychoneuroendocrinology. 2009; 34: 486–496.

[25] van Stegeren A, Rohleder N, Everaerd W, Wolf OT. Salivary alpha amylase as marker for adrenergic activity during stress: effect of betablockade. Psychoneuroendocrinology. 2006; 31: 137–141.

[26] Nater UM, La Marca R, Florin L, Moses A, Langhans W, Koller MM, et al. Stress-induced changes in human salivary alpha-amylase activity—associations with adrenergic activity. Psychoneuroendocrinology. 2006; 31: 49–58.

[27] Rohleder N, Nater UM, Wolf JM, Ehlert U, Kirschbaum C. Psychosocial stress‐induced activation of salivary alpha-amylase: an indicator of sympathetic activity? Annals of the New York Academy of Sciences. 2004; 1032: 258–263.

[28] Chojnowska S, Ptaszyńska-Sarosiek I, Kępka A, Knaś M, Waszkiewicz N. Salivary biomarkers of stress, anxiety and depression. Journal of Clinical Medicine. 2021; 10: 517.

[29] Ulrich-Lai YM, Herman JP. Neural regulation of endocrine and autonomic stress responses. Nature Reviews Neuroscience. 2009; 10: 397–409.

[30] Santos SVMD, Silva LAD, Terra FS, Souza AV, Espindola FS, Marziale MHP, et al. Association of salivary alpha-amylase with anxiety and stress in nursing professionals. Revista Latino—Americana de Enfermagem. 2021; 29: e3468.

[31] Swathi S, Pasupuleti S, Manyam R, Kumar Varma DP. The relationship between salivary alpha-amylase, nitric oxide, pain and anxiety-induced stress in patients during dental treatment. Journal of Oral and Maxillofacial Pathology. 2023; 27: 426.

[32] Sabbagh A, Nakata H, Abdou A, Kasugai S, Kuroda S. Fluctuation of salivary alpha-amylase activity levels and vital signs during dental implant surgery. International Journal of Implant Dentistry. 2021; 7: 58.

[33] Takai N, Yamaguchi M, Aragaki T, Eto K, Uchihashi K, Nishikawa Y. Effect of psychological stress on the salivary cortisol and amylase levels in healthy young adults. Archives of Oral Biology. 2004; 49: 963–968.

[34] Porporatti AL, Schroder ÂGD, Lebel A, Moreau N, Misery L, Alajbeg I, et al. Is burning mouth syndrome associated with stress? A meta-analysis. Journal of Oral Rehabilitation. 2023; 50: 1279–1315.

[35] Dibello V, Ballini A, Lozupone M, Custodero C, Cantore S, Sardone R, et al. Exploring the association of burning mouth syndrome with depressive and anxiety disorders in middle-aged and older adults: a systematic review. Journal of Personalized Medicine. 2023; 13: 1014.

[36] Pereira JV, Normando AGC, Rodrigues-Fernandes CI, Rivera C, Santos-Silva AR, Lopes MA. The impact on quality of life in patients with burning mouth syndrome: a systematic review and meta-analysis. Oral Surgery, Oral Medicine, Oral Pathology, and Oral Radiology. 2021; 131: 186–194.

[37] Shirasaki S, Fujii H, Takahashi M, Sato T, Ebina M, Noto Y, et al. Correlation between salivary α-amylase activity and pain scale in patients with chronic pain. Regional Anesthesia and Pain Medicine. 2007; 32: 120–123.

[38] López-Jornet P, Collado Y, Zambudio A, Pons-Fuster E, Castillo Felipe C, Tvarijonaviciute A. Chemosensory function in burning mouth syndrome a comparative cross-sectional study. Nutrients. 2021; 13: 722.

[39] Banu S, Jabir NR, Mohan R, Manjunath NC, Kamal MA, Vinod Kumar KR, et al. Correlation of toll-like receptor 4, interleukin-18, transaminases, and uric acid in patients with chronic periodontitis and healthy adults. Journal of Periodontology. 2015; 86: 431–439.

[40] La Fratta I, Tatangelo R, Campagna G, Rizzuto A, Franceschelli S, Ferrone A, et al. The plasmatic and salivary levels of IL-1β, IL-18 and IL-6 are associated to emotional difference during stress in young male. Scientific Reports. 2018; 8: 3031.

[41] Gao X, Lin J, Sun L, Hu J, Gao W, Yu J. Activation of the N-methyl-D-aspartate receptor and calcium/calmodulin-dependent protein kinase IIα signal in the rostral anterior cingulate cortex is involved in pain-related aversion in rats with peripheral nerve injury. Behavioural Brain Research. 2023; 452: 114560.

[42] Pancholi V. Multifunctional alpha-enolase: its role in diseases. Cellular and Molecular Life Sciences. 2001; 58: 902–920.